Research programme: immunomodulators - TapImmune/University of British Columbia
Latest Information Update: 07 Mar 2008
At a glance
- Developer TapImmune
- Class Small molecules
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 27 Feb 2004 Preclinical trials in Immunological disorders in USA (unspecified route)